Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Sunitinib in Advanced/Metastatic Urothelial Carcinoma
NCT00821327Phase 2Completed
- Sponsor
- US Oncology Network
- Start
- Aug 2008
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in urothelial carcinoma (UC), sponsored by US Oncology Network. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00821327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821327.